Mayne Pharma has agreed to a A$6.40-a-share cash takeover by Hungary’s Gedeon Richter, valuing the company’s equity at approximately A$604 million. The recommended scheme still depends on regulatory clearances, shareholder and court approval, and completion of Mayne’s international business sale.
- A$6.40 cash offer values equity at approximately A$604 million
- 99.4% premium to Mayne Pharma’s 16 November closing price
- Board recommendation backed by shareholders representing 22.14% of shares
- Scheme targeted for implementation in mid to late March 2027
- Completion depends on the Evaris Pharma divestment and regulatory approvals
Richter offer delivers a near-doubling of Mayne’s last close
Mayne Pharma Group Limited (ASX:MYX) has agreed to a A$6.40-a-share cash takeover from Hungary-based Gedeon Richter, putting an approximate A$604 million equity value on the ASX-listed specialty pharmaceutical company. The price represents a 99.4% premium to Mayne’s 16 November closing price, as well as premiums of 124% to its 30-day VWAP, 122% to its 90-day VWAP and 145% to its 180-day VWAP.
The offer is structured as a scheme of arrangement and is fully funded from Richter’s internal cash resources, with no financing condition. Mayne’s board has unanimously recommended the transaction, subject to there being no superior proposal and an independent expert concluding that the scheme is in shareholders’ best interests.
Shareholder support gives the scheme an early advantage
The recommendation already has meaningful shareholder backing. Funicular Funds, Bruce Mathieson and Trium Capital, which collectively hold 22.14% of Mayne’s ordinary shares, have each indicated that they intend to vote in favour of the scheme in the absence of a superior proposal. That support does not replace the formal shareholder vote, but it gives the transaction a substantial starting bloc.
Mayne’s deal comes as the company narrows its focus to the United States. Its international business sale to Evaris Pharma was announced at a A$55.5 million cash price and leaves the Women’s Health, Dermatology and DistributeRx operations at the centre of the remaining business. Completion of that divestment, which requires Australian Competition and Consumer Commission approval, is an express condition of the Richter scheme.
Regulatory and transaction conditions remain material
The scheme must clear the Foreign Investment Review Board process and US Hart-Scott-Rodino antitrust review, alongside Mayne shareholder approval, an independent expert’s favourable conclusion and Supreme Court approval. The parties also plan a voluntary filing with the Committee on Foreign Investment in the United States. The announcement says CFIUS could restrain the transaction if its process raised concerns, although the parties anticipate completing that process before the second court hearing.
The capital structure adds another moving part. Mayne’s convertible notes are scheduled to mature on 31 December 2026, and Rubric Capital may elect to redeem or convert them. If converted at A$5.356 a share, Rubric would receive 7,685,488 ordinary shares eligible to participate in the scheme. The transaction value already assumes conversion of the notes and takes account of equity incentives, based on approximately 94.4 million shares for valuation purposes.
Vote is expected in January with completion targeted for March
The first court hearing is expected in mid-December, followed by dispatch of the scheme booklet and independent expert’s report. Shareholders are currently expected to vote in late January, with the second court hearing and implementation targeted for mid to late March 2027. Until then, Mayne remains subject to ordinary-course operating restrictions and Richter has customary exclusivity protections, including no-shop, no-talk and matching rights for any superior proposal.
The scheme implementation deed sets both the ordinary break fee and the reverse break fee at A$6 million. The most immediate execution test is therefore not the headline premium but whether the Evaris sale, FIRB and US antitrust processes move through without disturbing the proposed timetable. Until the independent expert reports and the court process advances, the A$6.40 remains a contracted proposal rather than cash in shareholders’ accounts.
Bottom Line?
The premium is unusually large, but the path to payment runs through the Evaris divestment, regulatory clearances, the independent expert and a late-January shareholder vote.
Questions in the middle?
- Will the ACCC clear the Evaris transaction in time to satisfy Richter’s scheme condition?
- What conclusion will the independent expert reach on whether A$6.40 represents Mayne Pharma’s best available value?
- Will any competing proposal emerge before Richter’s matching rights and Mayne’s exclusivity restrictions expire?